Profiling Parkinson's disease
Networks
-
Datasets
-
Variables
-
The ProPark study aims to advance our understanding of the heterogeneity within the Parkinson’s disease (PD) population. The primary objective is to evaluate the role of both established and novel quantitative biomarkers in characterizing differences in disease progression, cognitive and neuropsychiatric symptoms, motor dysfunction, treatment response, and the occurrence of adverse drug reactions (ADRs) over a three-year follow-up period.
A secondary objective is the development of a comprehensive biobank, containing uniformly collected longitudinal clinical data, imaging data, wearable data and biological samples. This resource supports the identification and validation of biomarker panels and the application of data-driven approaches to uncover the biological and clinical diversity within the PD phenotype, predict treatment outcomes, and better understand individual susceptibility to ADRs.
This dataset is available to external researchers upon request, and we welcome collaborations that contribute to the advancement of personalized medicine in Parkinson’s disease.
Contact: propark@lumc.nl, propark@amsterdamumc.nl
Funding: ZonMW, AbbVie B.V., Pharmo Institute NV, Hoffmann-La Roche, H. Lundbeck A/S, Centre for Human Drug Research, Hersenstichting Nederland, Parkinson Vereniging, Stichting Alkemade-Keuls, Ventana Medical Systems, Inc, Stichting Woelse Waard, private
*Overview study procedures and timeline. Inclusion is still ongoing; the numbers mentioned are target values.*
*Overview study procedures and timeline. Inclusion is still ongoing; the numbers mentioned are target values.*
Design
- Study design
- Cohort
- Follow Up
-
- Yearly follow-up, for Parkinson patients.
- Twice yearly for a subgroup of Parkinson patients.
- One follow-up, two years after baseline assessment, for healthy controls.
- Supplementary Information
Number of participants
- Number of participants
- 865
- Number of participants with biosamples
- 830
- Supplementary Information
-
- Participants: 723 participants with Parkinson's Disease; 142 healthy control participants
- Biosamples: 691 participants with Parkinson's Disease; 139 healthy control participants
- Imaging data: 107 participants with Parkinson's Disease; 35 healthy control participants
Access
Availability of data and biosamples
| Data | |
| Biosamples | |
| Other |
Raw genetics and inertial measurement unit (accelerometer/gyroscope) data
|
Timeline
Populations
All participants: patients and healthy controls
Selection Criteria
- Minimum age
-
18
- Newborns
- Twins
- Countries
-
- Netherlands
- Ethnic Origin
-
- Health Status
-
- Parkinson's disease (patients)
- No history of neurological disorders that affect the brain or central nervous system (healthy controls)
Recruitment
Number of participants
- Number of participants
- Number of participants with biosamples
- Supplementary Information
Data Collection Event
All participants
- Start Date
-
2021-07
- End Date
-
2026-12
- Data sources
-
- Others : Inertial Measurement Unit data / Medication
People diagnosed with PD 15 years or fewer at baseline.
Selection Criteria
- Minimum age
-
18
- Newborns
- Twins
- Countries
-
- Netherlands
- Ethnic Origin
-
- Health Status
-
- Parkinson's disease
Recruitment
Number of participants
- Number of participants
- 675
- Number of participants with biosamples
- 675
Data Collection Event
- Start Date
-
2021-07
- End Date
-
2026-12
- Data sources
-
- Others : Inertial Measurement Unit data / Medication
gender and age matched healthy control participants
Selection Criteria
- Minimum age
-
18
- Newborns
- Twins
- Countries
-
- Netherlands
- Ethnic Origin
-
- Health Status
-
- No history of neurological disorders that affect the brain or central nervous system
Recruitment
Number of participants
- Number of participants
- 265
- Number of participants with biosamples
- 265
Data Collection Event
- Start Date
-
2021-07
- End Date
-
2026-12
- Data sources
-
- Others : Inertial Measurement Unit data / Medication